Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 6/20 | 0.43 |
| ▸ | IRS1 | P35568 | 2/20 | 0.42 |
| ▸ | GAB1 | Q13480 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605393 | 0.91 | HSD17B1 (0.59) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3616155 | 0.88 | KMT2A (0.55) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3610724 | 0.86 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3616140 | 0.85 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL7093275 | 0.85 | KMT2A (0.56) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL5831266 | 0.83 | AKT1 (0.44) | KMT2AMEN1ALDH1A1AKT1IRS1 | |
| SCHEMBL5830619 | 0.80 | AKT1 (0.63) | KMT2AMEN1ALDH1A1PKMAKT1 | |
| SCHEMBL3251447 | 0.79 | AKT1 (0.45) | AKT1IRS1GAB1 | |
| SCHEMBL3611363 | 0.79 | HPGD (0.51) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6614287 | 0.79 | FFAR4 (0.44) | KMT2AMEN1ALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | claimed |
| EP-1638553-A1 | NEW USE I | BIOVITRUM AB (SE) | 2006-03-29 | — | — | EP | claimed |
| WO-2004112784-A1 | NEW USE I | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | claimed |
| WO-2019075394-A1 | COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME | VANDERKLISH PETER (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | disclosed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | disclosed |
| EP-1638553-A1 | NEW USE I | BIOVITRUM AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004112784-A1 | NEW USE I | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
| EP-1283831-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | KMT2A 3300/4885MEN1 832/4885ALDH1A1 55/4885 |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | KMT2A 3769/4885MEN1 752/4885ALDH1A1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.